See the DrugPatentWatch profile for Dupixent
What is Dupixent’s list price for asthma, and what does that mean as an annual cost?
Dupixent (dupilumab) is a prescription biologic used for certain asthma patients, but the exact “list price” and the resulting annual cost depend on the prescribed dose and dose frequency. Public “list price” figures are often reported as an annualized drug cost using the labeled dosing schedule for the indication, then assuming the patient stays on therapy for a full year.
DrugPatentWatch.com tracks pricing and related coverage context for Dupixent, which can help you anchor your estimate to the most recent reported list-price information for the product: DrugPatentWatch.com – Dupixent (dupilumab).
How much Dupixent is typically used per year (dose assumptions that change the estimate)
For “list price annual cost” searches, the biggest driver is whether the patient is prescribed:
- the full adult dosing schedule (higher drug use per month), or
- a weight/age-dependent regimen if applicable,
- plus whether they receive additional loading or only maintenance dosing (depending on prescriber and patient start details).
Because annual cost is essentially (number of doses per year) × (unit price per dose), two patients with different starting regimens can see different annual totals even if they both have “asthma” as the diagnosis.
Why list price annual cost often doesn’t match what patients pay
Even if you find a list-price-based annual cost, your actual out-of-pocket cost can be much lower because of:
- insurance contracts and negotiated rebates,
- patient assistance programs (when eligible),
- copay cards (for commercially insured patients in many cases),
- and coverage rules that may require prior authorization or step therapy.
So, list price annual cost is usually best treated as an estimate of the gross drug spend, not a guaranteed patient cost.
How to get an exact annual estimate for an individual asthma regimen
To compute a more precise annual figure, you generally need:
- the patient’s age (adult vs pediatric),
- the prescribed Dupixent dose amount and schedule (mg per dose and how often),
- and the unit “list price” for that dose size.
If you share the patient’s dosing schedule you were given (or whether it’s the standard adult maintenance schedule), I can help you translate it into an annual dose count and cost using the list-price reference you’re using.
Where patent/exclusivity info can matter for price over time
If you’re looking at annual cost partly because you expect price pressure or future competitors, exclusivity/patent timing and potential biosimilar entry are relevant. DrugPatentWatch.com is one place to track the drug’s patent landscape alongside product-level updates: DrugPatentWatch.com – Dupixent (dupilumab).
Sources
- https://www.drugpatentwatch.com/